TW201542552A - 咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法 - Google Patents

咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法 Download PDF

Info

Publication number
TW201542552A
TW201542552A TW103130825A TW103130825A TW201542552A TW 201542552 A TW201542552 A TW 201542552A TW 103130825 A TW103130825 A TW 103130825A TW 103130825 A TW103130825 A TW 103130825A TW 201542552 A TW201542552 A TW 201542552A
Authority
TW
Taiwan
Prior art keywords
group
hydrocarbyl
optionally substituted
compound
heterohydrocarbyl
Prior art date
Application number
TW103130825A
Other languages
English (en)
Chinese (zh)
Inventor
Yingzhi Bi
Michael Walter Gardyan
Michael Alan Green
Godwin Kumi
Yulian Zhang
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of TW201542552A publication Critical patent/TW201542552A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW103130825A 2013-09-06 2014-09-05 咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法 TW201542552A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361874398P 2013-09-06 2013-09-06

Publications (1)

Publication Number Publication Date
TW201542552A true TW201542552A (zh) 2015-11-16

Family

ID=52628957

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103130825A TW201542552A (zh) 2013-09-06 2014-09-05 咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法

Country Status (10)

Country Link
US (1) US20150183791A1 (enExample)
EP (1) EP3041473A1 (enExample)
JP (1) JP2016529319A (enExample)
CN (1) CN105517552A (enExample)
AR (1) AR097543A1 (enExample)
AU (1) AU2014315075A1 (enExample)
CA (1) CA2923420A1 (enExample)
HK (1) HK1217659A1 (enExample)
TW (1) TW201542552A (enExample)
WO (1) WO2015035167A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6473146B2 (ja) 2013-10-11 2019-02-20 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ピロロトリアジンキナーゼ阻害剤
HRP20240644T1 (hr) 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
CA2966581A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
SG11201808830YA (en) 2016-04-06 2018-11-29 Lysosomal Therapeutics Inc Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11124516B2 (en) 2016-04-06 2021-09-21 BIAL-BioTech Investments, Inc. Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ[1,5-a]ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル-アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ[1,2-b]ピリダジン、置換イミダゾ[1,5-b]ピリダジン、関連化合物、および医学的障害の治療におけるその使用
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
SG11202001262QA (en) * 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in treating blood disorders
CN113164476A (zh) * 2018-09-28 2021-07-23 代表亚利桑那大学的亚利桑那校董会 Dyrk1/clk的小分子抑制剂及其用途
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460417T1 (de) * 2005-03-23 2010-03-15 Hoffmann La Roche Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2663091A1 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
UY31676A1 (es) * 2008-02-28 2009-09-30 "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
EA019507B1 (ru) * 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
JP5641664B2 (ja) * 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap イミダゾ[1,2−b]ピリダジン誘導体およびPDE10阻害剤としてのそれらの使用
KR101953210B1 (ko) * 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
CA2851155C (en) * 2011-10-14 2021-02-23 Ambit Biosciences Corporation Heterocyclic compounds and methods of use thereof
WO2013059589A1 (en) * 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
HUE036040T2 (hu) * 2012-03-09 2018-06-28 Lexicon Pharmaceuticals Inc Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
US8969565B2 (en) * 2012-03-09 2015-03-03 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JP2016510764A (ja) * 2013-03-07 2016-04-11 カリフィア バイオ, インク.Califia Bio, Inc. 混合系キナーゼ阻害剤および治療法
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity

Also Published As

Publication number Publication date
JP2016529319A (ja) 2016-09-23
AR097543A1 (es) 2016-03-23
AU2014315075A1 (en) 2016-03-10
HK1217659A1 (zh) 2017-01-20
CA2923420A1 (en) 2015-03-12
CN105517552A (zh) 2016-04-20
US20150183791A1 (en) 2015-07-02
EP3041473A1 (en) 2016-07-13
WO2015035167A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
TW201542552A (zh) 咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法
JP6418950B2 (ja) ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法
CN105517553B (zh) 基于吡唑并[1,5-a]嘧啶的化合物、包含其的组合物和其使用方法
TWI781935B (zh) 經取代之吲唑於治療及預防動物之疾病之用途
TW201341385A (zh) 咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法
TW201341387A (zh) 芳基醚結構之激酶抑制劑
CN106103447A (zh) 连接物关联激酶1的抑制剂、包含其的组合物、及其使用方法
HK1217658B (zh) 基於吡唑并[1,5-a]嘧啶的化合物、包含其的组合物和其使用方法
HK1201257B (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
HK1226065B (zh) 连接物关联激酶1的抑制剂、包含其的组合物、及其使用方法
HK1242324A1 (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs